XML 43 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
Organization and Operations
 12 Months Ended
Dec. 31, 2012
Organization and Operations [Abstract]  
Organization and Operations
1.
Organization and Operations

The Company

Cytori (NASDAQ: CYTX) is developing cell therapies for cardiovascular disease and for the repair of soft tissue injuries and burns. Cytori's cell therapy utilizes a patient's own adipose derived stem and regenerative cells, uniquely optimized and formulated for specific therapeutic applications.
 
Principles of Consolidation

The accompanying consolidated financial statements include our accounts and those of our subsidiaries.  All significant intercompany transactions and balances have been eliminated.  Management evaluates its investments on an individual basis for purposes of determining whether or not consolidation is appropriate.  In instances where we do not demonstrate control through decision-making ability and/or a greater than 50% ownership interest, we account for the related investments under the cost or equity method, depending upon management's evaluation of our ability to exercise and retain significant influence over the investee. Our investment in the Olympus-Cytori, Inc. joint venture has been accounted for under the equity method of accounting (see note 3 for further details).
 
We have three subsidiaries located in Japan, Switzerland and India that have been established primarily to support our sales and marketing activities in these regions

Certain Risks and Uncertainties

Our prospects are subject to the risks and uncertainties frequently encountered by companies in the early stages of development and commercialization, especially those companies in rapidly evolving and technologically advanced industries such as the biotech/medical device field. Our future viability largely depends on our ability to complete development of new products and receive regulatory approvals for those products. No assurance can be given that our new products will be successfully developed, regulatory approvals will be granted, or acceptance of these products will be achieved. The development of medical devices for specific therapeutic applications is subject to a number of risks, including research, regulatory and marketing risks. There can be no assurance that our development stage products will overcome these hurdles and become commercially viable and/or gain commercial acceptance.

Capital Availability
    We incurred net losses of $32,279,000, $32,451,000 and $27,494,000 for the years ended December 31, 2012, 2011 and 2010, respectively.  We have an accumulated deficit of $274,728,000 as of December 31, 2012.  Additionally, we have used net cash of $32,193,000, $35,323,000 and $23,574,000 to
    fund our operating activities for years ended. December 31, 2012, 2011 and 2010, respectively.  To date, these operating losses have been funded primarily from outside sources of invested capital and gross profits. During 2012, we expanded our commercialization activities while
    simultaneously pursuing available financing sources to support operations and growth.  
 
  We have had, and we will likely continue to have, an ongoing need to raise additional cash from outside sources to fund our future operations.  We believe we have sufficient cash to fund operations into the third quarter of 2013, which includes minimum liquidity requirements of the     
  Amended and Restated Loan and Security Agreement, which requires that we make principal payments of $825,000 per month along with accrued interest throughout 2013 and maintain at least three months of cash on hand.  In order to fund operations and our continued commercialization   
  efforts through the next twelve months, we are pursuing additional funding through either strategic corporate partnerships, debt restructuring or future issuances of equity or debt securities in addition to our gross profits. We have an established history of raising capital through all these
  platforms, and are currently involved in negotiations with multiple parties.  In the absence of sufficient positive cash flows from operations,  no assurance can be given that we can generate sufficient revenue to cover operating costs or that additional financing will be available to us and, if
  available, on terms acceptable to us in the future.

Without this additional capital, cash generated from sales and containment of costs will not provide adequate funding indefinitely at their current levels.  If we cannot raise sufficient capital, we would need to reduce our research, development, and administrative operations, including reductions of our employee base and the deferral of ongoing development projects, to focus almost entirely on the supply of current products to existing distribution channels and our thermal burn contract arrangement with BARDA.  As a result, such reductions would negatively affect our ability to achieve certain other corporate goals.